Cognition Therapeutics (NASDAQ:CGTX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $3.00 target price on the stock. HC Wainwright‘s price target suggests a potential upside of 415.29% from the stock’s previous close.
Several other equities analysts have also issued reports on CGTX. Wall Street Zen lowered Cognition Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Monday, September 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.50.
View Our Latest Stock Analysis on CGTX
Cognition Therapeutics Stock Down 3.1%
Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Equities research analysts predict that Cognition Therapeutics will post -0.22 earnings per share for the current year.
Hedge Funds Weigh In On Cognition Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. Sigma Planning Corp raised its position in Cognition Therapeutics by 7.3% in the second quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock worth $417,000 after acquiring an additional 24,500 shares during the period. Bryn Mawr Trust Advisors LLC purchased a new position in Cognition Therapeutics in the second quarter valued at about $33,000. StoneX Group Inc. purchased a new position in Cognition Therapeutics in the third quarter valued at about $30,000. Lido Advisors LLC purchased a new position in Cognition Therapeutics in the third quarter valued at about $44,000. Finally, Marshall Wace LLP bought a new position in shares of Cognition Therapeutics during the 3rd quarter valued at approximately $68,000. Institutional investors own 43.35% of the company’s stock.
About Cognition Therapeutics
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule treatments for neurodegenerative diseases and other disorders affecting the central nervous system and retina. The company’s lead drug candidate, CT1812 (zervimesine), is an oral small molecule designed to target the sigma-2 receptor complex and disrupt the effects of toxic amyloid-beta oligomers on brain cells. Cognition has studied CT1812 in clinical programs for Alzheimer’s disease and dementia with Lewy bodies, and has also investigated its potential in retinal disease.
Further Reading
- Five stocks we like better than Cognition Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
